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INTRODUCTION AND EXECUTIVE SUMMARY
The Greens/EFA Internet Core Group in the European Parliament, and a
collection of its individual members,2 commissioned this analysis of
potential impacts of the Anti-Counterfeiting Trade Agreement (ACTA) 3 on
access to medicines in developing countries.”4 On the whole, ACTA
negotiators created an agreement that shifts international “hard law” rules
and “soft law” encouragements toward making enforcement of intellectual
property rights in courts, at borders, by the government and by private
parties easier, less costly, and more “deterrent” in the level of penalties. In
doing so, it increases the risks and consequences of wrongful searches,
seizures, lawsuits and other enforcement actions for those relying on
intellectual property limitations and exceptions to access markets, including
the suppliers of legitimate generic medicines. This, in turn, is likely to make
affordable medicines more scarce and dear in many countries.
1

Sean Flynn is a Professorial Lecturer & Associate Director, Program on Information
Justice and Intellectual Property (PIJIP), American University Washington College of Law.
Bijan Madhani is a Program Fellow at PIJIP. Research assistance was provided by Michael
Vasquez, also a Program Fellow at PIJIP.
2
The Members of Parliament include: Jan Albrecht, Germany; Eva Lichtenberger,
Austria; Judith Sargentini, Netherlands; Carl Schlyter, Sweden; Karima Delli, France;
Sandrine Bélier, France; Franziska Keller, Germany; Christian Engström, Sweden.
3
Anti-Counterfeiting Trade Agreement, Dec. 3, 2010 [hereinafter ACTA Text–Dec. 3,
2010],
available
at
http://dfat.gov.au/trade/acta/Final-ACTA-text-following-legalverification.pdf.
4
Proposal for a Study: ACTA and its impact on the access to medicine, ACT ON
ACTA, http://en.act-on-acta.eu/ACTA_and_its_impact_on_the_access_to_medicine.
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The ACTA process and substance is counter to two sets of specific
instructions contained in European Parliament resolutions and supported by
international human rights law.
(1) First, the negotiation disregarded specific Parliament instructions
stating that processes for international law making impacting access to
medicines and other important social interests be open, transparent and
participatory.
(2) Second, the substance of the Agreement violates Parliament
demands that trade agreements in general, and ACTA specifically, not
include “TRIPS-plus” measures that may restrict the global trade in
affordable medicines. ACTA provisions that are TRIPS-plus and could
restrict access to essential medicines in developing countries and
elsewhere include:
● Border measures requirements that expand the scope of
authorized seizures to any case where a border agent “suspects”
a medicine’s label of being “confusingly similar” to a brand.
● Injunction provisions that require all ACTA members to put in
place the basic legal elements that were used in the “Dutch
seizures” cases in the EU, enabling authorities in one country
issue injunctions preventing goods from entering commerce in a
third country without that third country’s officials ever passing
on whether the item would infringe its own laws.
● Third-party liability rules that increase risks of erroneous
injunctions and seizures of property from distributors, shippers,
procurement agents and component suppliers of any generic
product suspected of having a “confusingly similar” label.
● Damages provisions that over-deter lawful conduct by
encouraging determinations of damages in poorer countries
based on the “market price” or “suggested retail price” of a
branded product, even where that price is intentionally set at a
level that excludes the great majority of a population form
access to the product.
● Information disclosure requirements that could be used by
right holders to discover details on distribution chains of generic
companies and mount aggressive and expensive litigation
against suppliers and intermediaries to deter generic entry into
key markets.
● Expansion of criminal liability to cases where a supplier did
not intentionally create or use the counterfeit label itself, thus
raising the (over-)deterrent effect of trademark law for
importers, including those of generic medicines.
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●

Expansion of seizure and destruction rules to require that, for
example, absent “exceptional circumstances,” a medicine found
to have a minor trademark infringement on a label be destroyed
rather than re-labeled and re-sold.

Given these paramount procedural and substantive flaws, this opinion
concludes that the EU Parliament should withhold consent to ACTA.
I.

ACTA’S PROCESS DID NOT COMPLY WITH PARLIAMENT MANDATES ON
TRANSPARENCY AND STAKEHOLDER PARTICIPATION
ACTA is a sweeping legal framework agreement, creating a minimum
standards that require or prevent changes in domestic legislation that affect
a broad range of public interests.5 Unlike in multilateral institutions,
including the World Intellectual Property Organization, where similar
agreements are sometimes crafted, ACTA did not afford basic public
participation resources. Ongoing releases of negotiation texts and
background materials, institutionalized and regular briefings of civil society
and the general public and public access to the negotiation venue were all
absent.6
Open policy making process are needed to promote democratic
legitimacy and respect for human rights,7 as well as for the instrumental aim
of promoting better policy outcomes more reflective of the fullest range of
stakeholder interest. Recognizing these values and objectives, the European
Parliament’s March 2010 resolution on ACTA contains at least nine
specific demands for transparency and open process.8 Each of these
5

See Sean Flynn, ACTA’s Constitutional Problem: The Treaty is not a Treaty, 26 AM.
U. INT’L L. REV.. 903, 908-912 (2011).
6
See Jeremy Malcolm, Public Interest Representation in Global IP Policy Institutions
20-21 (Program on Info. Justice and Intellectual Prop. Working Paper No. 6, 2010),
available at http://digitalcommons.wcl.american.edu/research/9 (demonstrating that ACTA
negotiations failed to satisfy best practices for transparency and public participation).
7
See U.N. Special Rapporteur Anand Grover, Promotion and Protection of All Human
Rights, Civil, Political, Economic, Social, and Cultural Rights, Including the Right to
Development: Rep. of the Special Rapporteur on the right of everyone to the enjoyment of
the highest attainable standard of physical and mental health, ¶ 4, U.N. Doc.
A/HRC/11/12 (Mar. 31, 2009) (describing human rights requirements to promote broad
public participation in health policy making).
8
See generally Eur. Parl. res. of 10 March 2010 on the transparency and state of play
of
the
ACTA
negotiations,
P7_TA(2010)0058
(2010),
available
at
http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+P7-TA-20100058+0+DOC+XML+V0//EN&language=EN. See also Eur. Parl. res. on the AntiCounterfeiting Trade Agreement (ACTA), B7‑0617/2010 (2010), available at
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demands and the response of the ACTA negotiation are detailed in the chart
below. In short, ACTA’s negotiating process violated every one of the EU
Parliament’s open process demands.

European Parliamentary Resolution March 2010

ACTA Process (post-resolution)

2. Expresses its concern over the lack of a transparent
process in the conduct of the ACTA negotiations, a state of
affairs at odds with the letter and spirit of the TFEU [Treaty
on the Functioning of the European Union];

Process not dramatically improved. No Public hearings held
on draft text. Public health representatives continue to be
consulted only in closed-door sessions with no access to
text.

[I]s deeply concerned that no legal base was established
before the start of the ACTA negotiations and that
parliamentary approval for the negotiating mandate was not
sought;

No legal base established before conclusion of ACTA
negotiations.

3. Calls on the Commission and the Council to grant public
and parliamentary access to ACTA negotiation texts and
summaries, in accordance with the Treaty and with
Regulation (EC) No 1049/2001 of 30 May 2001 regarding
public access to European Parliament, Council and
Commission documents;

One public release of draft negotiating text in April 2010.9
Parliament given ongoing access to negotiating drafts after
April, but public is not given similar access.

4. Calls on the Commission and the Council to engage
proactively with ACTA negotiation partners to rule out any
further negotiations which are confidential as a matter of
course and to inform Parliament fully and in a timely
manner about its initiatives in this regard; expects the
Commission to make proposals prior to the next negotiation
round in New Zealand in April 2010, to demand that the
issue of transparency is put on the agenda of that meeting
and to refer the outcome of the negotiation round to
Parliament immediately following its conclusion;

Whether the Commission in fact pressured other partners to
increase transparency is unknown because all negotiation
venues and positions remained secret through the
finalization of text in December 2011. Rounds of
negotiations continued to be held in locations that were
undisclosed until hours before their formal start.

5. Stresses that, unless Parliament is immediately and fully
informed at all stages of the negotiations, it reserves its right
to take suitable action, including bringing a case before the
Court of Justice in order to safeguard its prerogatives;

After the resolution, the European Parliament’s
International Trade Committee (INTA) was given access to
negotiating text, but under rules prohibiting the sharing of
text with uncleared constituents stakeholders.
The Commission is now being sued by one MEP for a
failure to meet Parliament’s demands.10

http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+MOTION+B72010-0617+0+DOC+XML+V0//EN; Eur. Parl. res. on ACTA – preparing for the consent
procedure,
B7‑0619/2010
(2010),
available
at
http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-20100619&language=EN (demonstrating that political groups Greens/EFA and ALDE tabled
identical resolutions containing policies similar to the European Parliament Resolution).
9
Anti-Counterfeiting Trade Agreement: PUBLIC Predecisional/Deliberative Draft,
April 2010, available at http://trade.ec.europa.eu/doclib/docs/2010/april/tradoc_146029.pdf
[hereinafter ACTA Text–Apr. 2010].
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6. Deplores the calculated choice of the parties not to
negotiate through well-established international bodies,
such as WIPO and WTO, which have established
frameworks for public information and consultation;

ACTA was not moved to a multilateral forum.

8. Welcomes affirmations by the Commission that any
ACTA agreement will be limited to the enforcement of
existing IPRs, with no prejudice for the development of
substantive IP law in the European Union”

In the end, as discussed below, ACTA limits the ability to
develop limitations and exceptions to intellectual property
rights enforcement, thereby impacting the practical reach of
intellectual property rights.

9. Calls on the Commission to continue the negotiations on
ACTA and limit them to the existing European IPR
enforcement system against counterfeiting;

EU academic analysis indicates that ACTA goes beyond the
acquis communautaire.11

[C]onsiders that further ACTA negotiations should include
a larger number of developing and emerging countries, with
a view to reaching a possible multilateral level of
negotiation;

No more developing countries are added to the negotiation.
Despite the proclaimed intent to make ACTA a new global
standard,12 only two of the 37 negotiating countries,
Morocco and Mexico, were developing countries.

II.

ACTA DOES NOT COMPLY WITH PARLIAMENT ORDERS TO EXCLUDE
TRIPS-PLUS PROVISIONS ON MEDICINES
Following controversial interpretations of TRIPS requirements in a
series of attempts to challenge facially compliant access to medicine
policies in developing countries in the mid 1990s, a body of legal norms
emerged that are critical of so-called “TRIPS-plus” measures that heighten
intellectual property for medicines in developing countries beyond the plain
10

See generally Case T-301/10, In 't Veld v Comm’n, 2010 O.J. (C 260) 18-19 (Sept.
25,
2010),
available
at
http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2010:260:0018:0019:EN:PDF.
See
also Eur. Comm. for Trade Karel De Gucht, Answer to a written question - ACTA — a law
enforcement
treaty?,
¶5,
E-8847/2010,
(2010),
available
at
http://www.europarl.europa.eu/sides/getAllAnswers.do?reference=E-20108847&language=EN (refusing to answer whether Commission has “compromised the rules
and regulations on access to information and transparency in the European Union” because
“this issue is currently the object of a court case lodged by an Member of the European
Parliament against the Commission”).
11
See Opinion of European Academics on the Anti-Counterfeiting Trade Agreement,
Institute
for
Legal
Informatics
(2011),
available
at
http://www.iri.unihannover.de/tl_files/pdf/ACTA_opinion_200111_2.pdf [hereinafter European Academics]
(finding that: “ACTA provisions are not entirely compatible with EU law and will directly
or indirectly require additional action on the EU level,” and advising, “as long as
significant deviations from the EU acquis or serious concerns on fundamental rights, data
protection, and a fair balance of interests are not properly addressed, to withhold
consent.”).
12
See Office of the U.S. Trade Representative, 2008 Special 301 Report 4 (2008),
available
at
http://www.ustr.gov/sites/default/files/asset_upload_file553_14869.pdf
(explaining that ACTA is designed to ultimately create new “global” enforcement
standards).
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meaning of TRIPS minimum standards.13 Implementing this trend toward
protection of access to medicines in international trade policy, the European
Parliament has repeatedly enjoined the Commission from negotiating
agreements with developing countries containing TRIPS-plus provisions on
medicines. Specifically:
● In 2007 the Parliament resolved that the Commission should not
negotiate “pharmaceutical-related TRIPS-plus provisions affecting
public health and access to medicines” in “future bilateral and
regional agreements with developing countries.”14
● In March 2010, the Parliament specifically addressed the issue with
respect to ACTA, resolving that “ACTA provisions, notably
measures aimed at strengthening powers for cross-border inspection
and seizure of goods, should not affect global access to legitimate,
affordable and safe medicinal products – including innovative and
generic products – on the pretext of combating counterfeiting.”15
ACTA does not comply with these mandates. The ACTA agreement
itself has several developing country members. And the policies it
implements, by raising border controls in “in-transit” and exporting
countries regardless of the ultimate country of destination, can impact every
developing country that relies on shipments from or through European
13

See Doha Declaration on TRIPS and Public Health, World Trade Organization,
Ministerial Declaration of 14 November 2001, WT/MIN(01)/DEC/1, 41 I.L.M. 746 ¶4
(2002) [hereinafter Doha Declaration] (affirming that TRIPS “should be interpreted and
implemented in a manner supportive of WTO members' right to protect public health and,
in particular, to promote access to medicines for all,” and reaffirming “the right of WTO
members to use, to the full, the provisions in the TRIPS Agreement, which provide
flexibility for this purpose”); U.N. Special Rapporteur Anand Grover, Promotion and
Protection of All Human Rights, Civil, Political, Economic, Social, and Cultural Rights,
Including the Right to Development: Rep. of the Special Rapporteur on the right of
everyone to the enjoyment of the highest attainable standard of physical and mental health,
¶ 108, U.N. Doc. A/HRC/11/12 (Mar. 31, 2009) (“Developing countries and LDCs should
not introduce TRIPS-plus standards in their national laws. Developed countries should not
encourage developing countries and LDCs to enter into TRIPS-plus FTAs and should be
mindful of actions which may infringe upon the right to health.”).
14
Eur. Parl. res. of 12 July 2007 on the TRIPS Agreement and access to medicines,
P6_TA(2007)0353, available at http://www.europarl.europa.eu/sides/getDoc.do?pubRef=//EP//TEXT+TA+P6-TA-2007-0353+0+DOC+XML+V0//EN (resolving further that
“measures to tackle counterfeiting need to be . . . reinforcing the regulatory capacity of the
national authorities [not] increasing levels of intellectual property protection.”).
15
Eur. Parl. res. of 10 March 2010 on the transparency and state of play of the ACTA
negotiations,
P7_TA(2010)0058
(2010),
available
at
http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+P7-TA-20100058+0+DOC+XML+V0//EN&language=EN.
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ports. In this context, ACTA contains over a dozen provisions that require
or encourage member countries to raise intellectual property enforcement
standards on medicines, including on those medicines ultimately destined
for developing countries. These concerns are described in more detail
below.
A. Border Measures
One of ACTA’s most serious threats to access to medicines comes from
the raising of TRIPS requirements for border seizures of suspected
products. The border provisions were some of the most controversial
aspects of ACTA. The controversies were triggered by a series of wrongful
uses of border measures in the EU to detain lawful shipments of generics to
and from developing countries, now generally referred to as the “Dutch
Seizures.”16 In recognition of the abusive nature of the Dutch Seizure cases,
negotiators exempted patents from application of the Border Measures
sections.17 But medicines are also subject to trademark rules and medicines
were wrongfully detained elsewhere in Europe on trademark grounds.18
ACTA’s dramatic expansion of TRIPS border measure requirements,
including requiring the authorization of seizures where border agents
“suspect” a medicine’s label of being “confusingly similar” to a brand, will
increase the risk of seizures of legitimate medicines.19 The lowering of
16

See Kimberlee Weatherall, Politics, Compromise, Text and the Failures of the AntiCounterfeiting Trade Agreement, 33 SYDNEY L. REV. 229, 245 (2011); Intervention by
India, TRIPS Council, Agenda item ‘M’ – Other Business – Public Health dimension of
TRIPS
Agreement
2
(Feb.
4,
2009),
http://ip-watch.org/weblog/wpcontent/uploads/2009/03/intervention-by-india.doc; Statement by Brazil, TRIPS Council,
Agenda item ‘M’ – Other Business – Public Health dimension of TRIPS Agreement ¶15,
16 (Feb. 4, 2009), http://ip-watch.org/weblog/wp-content/uploads/2009/03/intervention-bybrazil.pdf (stating the importance of the TRIPS flexibilities for public health via their
inclusion in the Doha Declaration, while noting that the actions of the Dutch authorities
did not comport with those flexibilities).
17
See ACTA Text–Dec. 3, 2010, supra note 3, art. 13 n.6 (stating “[t]he Parties agree
that patents and protection of undisclosed information do not fall within the scope of this
section”).
18
An example is a German case where drugs were seized for bearing the INN name
(mandated for labels in most countries) that was thought to be “confusingly similar” to a
brand name. See generally Press Release, Health Action International, Another Seizure of
Generic
Medicines,
(June
5,
2009),
available
at
http://www.haiweb.org/19062009/5%20Jun%202009%20Press%20release%20Seizure%20
of%20generic%20medicines%20in%20Frankfurt.pdf.
19
Compare Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr.
15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C,
art. 58, 108 Stat. 4809, 1869 U.N.T.S. 299 [hereinafter TRIPS] (requiring authorization to
seize suspected counterfeit trademark goods in response to prima facie evidence from the
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minimum standards for procedural rights and evidence before seizures may
also implicate international and European human rights norms governing
fair trials and takings of property.20
B. Injunctions And Provisional Measures
ACTA expands injunction and provisional measures requirements that
could stop flows of legitimate medicines within and beyond member
countries, even with no determination of an intellectual property violation.21
Specifically:
● While TRIPS permits equitable relief solely with respect to goods
entering the channels of commerce within a country’s jurisdictional
territory,22 ACTA expands injunction requirements to include ther
prevention of any alleged infringement, including infringements
taking place wholly outside the ACTA member country.
● ACTA extends TRIPS requirements to authorize provisional
measures from actual infringements to “suspect” goods,23 thus
lowering the evidentiary threshold under which medicines and other
goods may be subject to provisional orders interrupting supply.
● ACTA’s injunction requirements apply to patents, unless expressly
exempted by an individual country.24
right holder, and allowing, but not requiring, ex officio restraints of imports), with ACTA
Text–Dec. 3, 2010, supra note 3, art. 13 n.6 (stating “[t]he Parties agree that patents and
protection of undisclosed information do not fall within the scope of this section”); id. art.
16:1(a) (stating that Parties “shall adopt” procedures where its customs authorities suspend
the release of suspect goods on their own initiative); id. art. 16:2 (omitting any reference to
infringements of domestic or foreign intellectual property law);
20
Compare TRIPS art. 58 (noting that competent authorities may act upon their own
initiative in suspending the release of goods when they have acquired prima facie evidence
of infringement), with ACTA Text–Dec. 3, 2010, supra note 3, arts. 16:1(a), 16:2(b), 17:1
(mentioning a prima facie evidentiary requirement for suspensions only in the case of
requests by right holders, not when customs authorities act on their own).
21
See ACTA Text–Dec. 3, 2010, supra note 3, art. 12:1(a) (stating that judicial
authorities have the authority to order provisional measures to “prevent an infringement of
any intellectual property right from occurring”).
22
Compare TRIPS arts. 44.1, 50.1(a) (stating that judicial authorities have the
authority to order injunctions and provisional measures to prevent infringing goods from
entry into the channels of commerce “in their jurisdiction”), with ACTA Text–Dec. 3,
2010, supra note 3, arts. 8:1, 12:1(a) (including reference to the channels of commerce, but
omitting the “in their jurisdiction” language).
23
See ACTA Text–Dec. 3, 2010, supra note 3, art. 12:3 (“each Party shall provide
that, in civil judicial proceedings, its judicial authorities have the authority to order the
seizure or other taking into custody of suspect goods . . .”).
24
See id. art. 7 n.2 (“A Party may exclude patents and protection of undisclosed
information from the scope of this Section.”) (emphasis added).
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Together, these expansions of authority require all member countries to
put in place the basic legal elements similar to those used in the “Dutch
seizures.” Specifically, they enable authorities in one country to issue
injunctions preventing goods from entering commerce in a third country
without that third country’s officials ever passing on whether the item
would infringe its own laws. Because medicines contain trademarks as well
as patents, merely eliminating all application of ACTA provisions to patents
will not solve this problem.25
C. Third-Party Liability
ACTA expands potential liability to third-parties that supply goods or
services to medicines suppliers accused of infringing intellectual property
rights. As discussed above, ACTA allows provisional measures
(preliminary injunctions) against third parties to prevent an infringement
from occurring by another party and allows injunctions against third parties
to prevent goods that infringe an IP right from entering into the channels of
commerce.26
The scope of third-parties that can be held liable is potentially very
broad. In the pharmaceutical context, third parties potentially liable under
ACTA standards could include distributors, shippers, procurement agents
and component suppliers.27 Third-party enforcement, including injunctions
and other interruption of supplies based on a minimal level of suspicion,
may deter various businesses in the supply chain from dealing in the trade
of legitimate generic medicines.
D. Damages
ACTA’s provisions on damages encourage courts to adopt punitive
measures of damages that may over-deter generic companies from
competing with brand holders, particularly in developing country markets.
ACTA expands TRIPS requirements by delineating specific measures of
damages that each member’s authorities “shall consider.”28 The measures
25

See Directorate-General for External Policies, The Anti-Counterfeiting Trade
Agreement (ACTA): An Assessment, 61, EXPO/B/INTA/FWC/2009-01/Lot7/12 (July 11,
2011) [hereinafter ACTA Assessment] (noting that trademarks are frequently litigated in
the medicines market and that trademark concerns frequently hinder generic medicine
market penetration)
26
ACTA Text–Dec. 3, 2010, supra note 3, arts. 8:1, 12:1(a).
27
Brook K. Baker, ACTA: Risks of Third-Party Enforcement to Access to Medicines,
26 AM. U. INT’L L. REV. 579, 581 (2011).
28
Compare TRIPS art. 45 (suggesting methods of determining damages that judicial
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suggested by ACTA, including lost profits and the “market price” or
“suggested retail price” of a branded product, 29 are highly inappropriate for
developing countries. This standard would apply to every trademark
infringement action on a challenged label, and could apply as well in patent
litigation. In a world where brand holders traditionally offer no discounts to
developing countries for high priced medicines, setting damages for
intellectual property violations based on these factors rewards exclusionary
pricing and over-deters generic entry to the detriment of access to medicines
concerns.
E. Information Disclosure
ACTA expands requirements to authorize disclosures of information to
rights holders in ways that may deter companies from working with generic
suppliers and may enable strategic litigation to create barriers to generic
entry. ACTA’s TRIPS-plus requirements in this area include:
● Requiring disclosure of information about “alleged,” rather than
proven, infringers;30
● Removing a TRIPS safeguard that countries need not grant
information to rights holders if it “would be out of proportion to the
seriousness of the infringement”;31 and
● Extending the duty to disclose information to a much broader range
of information, including that “regarding any person involved in any
aspect of the infringement or alleged infringement,” and “regarding
the means of production or the channels of distribution of the
infringing or allegedly infringing goods or services.”32
In practical effect, the provisions could be used by right holders to
discover details on distribution chains of generic companies and mount
aggressive and expensive litigation against suppliers and intermediaries to
deter generic entry into key markets.
F. Criminal Offenses
ACTA dramatically expands the scope of common trademark violations
authorities may authorize), with ACTA Text–Dec. 3, 2010, supra note 2, arts. 9:3, 9:3(b)
n.3 (including the TRIPS suggestions plus recommended formulas for calculating
damages).
29
See ACTA Text–Dec. 3, 2010, supra note 3, arts. 9:3(b) n.3.
30
Id. art. 11.
31
Compare TRIPS art. 47, with ACTA Text–Dec. 3, 2010, supra note 3, art. 11
(reducing the safeguard to a “justified request of the right holder”).
32
ACTA Text–Dec. 3, 2010, supra note 3, art. 11.
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that can be considered criminal, thus raising the risks for generic suppliers
that rely on similar labeling to create consumer confidence and meet
regulatory requirements. ACTA’s definition of criminal offences for
trademark infringement include the intentional importation and use of the
good containing a counterfeited mark, rather than the act of counterfeiting
itself.33 One could thus be held liable under this standard by intentionally
importing a good with a counterfeit label, even if that person did not
intentionally create or use, or perhaps eve know of, the counterfeit label
itself. This could greatly expand the number of cases of trademark misuse
that could be considered criminal, thus raising the (over-)deterrent effect of
trademark law for importers of generic medicines and other goods.34
G. Seizure And Destruction Of Goods
ACTA requires that, “except in exceptional circumstances,” all
intellectual property infringing goods must be destroyed without
compensation. This is a dramatic expansion of the TRIPS requirements for
destruction of goods. ACTA could be interpreted to require that, for
example, absent “exceptional circumstances,” a medicine found to have a
minor trademark infringement on a label be destroyed rather than re-labeled
and re-sold. ACTA also expands criminal seizures from being a remedy for
proven violations of criminal law to require seizures of “suspected”
violations.35 This expansion may have the effect of leading to more seizures
of legitimate medicines, particularly when coupled with the expansion of
criminal liability discussed above.
Each of these provisions is analyzed in more detail in the following Part,
providing a section by section analysis of the ACTA text.
III. SECTION BY SECTION ANALYSIS
This Part presents a section by section analysis of provisions in the
ACTA agreement that may negatively impact access to medicines in
developing countries. Each ACTA section identified is quoted in its
applicable parts followed by a quotation of the provisions of TRIPS that
bear on the same topic. An analysis section describes the ways in which the
33

Compare TRIPS art. 61 (providing for criminal procedures in the event of wilful
trademark counterfeiting on a commercial scale), with ACTA Text–Dec. 3, 2010, supra
note 3, art. 23:2 (adding the provision for criminal procedures in the event of willful
importation) (emphasis added).
34
See ACTA Assessment at 61.
35
Compare TRIPS art. 61 (providing for criminal seizures in cases involving actual
infringing goods), with ACTA Text–Dec. 3, 2010, supra note 3, art. 25.1 (discussing
“suspect” goods and “alleged” offences).
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ACTA text exceeds the minimum standards in the TRIPS agreement and
may negatively impact access to medicines in developing countries.

A. Chapter II, Section 2, fn. 2: CIVIL ENFORCEMENT (SCOPE OF
PROVISIONS)
A Party may exclude patents and protection of undisclosed
information from the scope of this Section.

1. Related TRIPS Provisions
TRIPS Sec. 1, Art. 1(2) – Nature and Scope of Obligations
● For the purposes of this Agreement, the term "intellectual property"
refers to all categories of intellectual property that are the subject of
Sections 1 through 7 of Part II.
2. Analysis
Although TRIPS provisions cover a broad range of intellectual property
rights, many of its enforcement and remedy provisions are limited to
trademark counterfeiting and copyright piracy.36 Public health advocates
have been particularly concerned with new rules that would extend
remedies and measures traditionally restricted to copyrights or trademark
counterfeiting to patents. One key reason for concern is that patent
violations are extremely technical and hard to detect. Extending
enforcement measures that rely on non-expert determinations, remedies
without full hearings, and extension of liability to third parties and
intermediaries who may have no ability to detect patent law violations may
over-deter business dealings with generic drug makers.
In early drafts of ACTA, there was no substantive discussion of the
scope of the civil enforcement section.37 There was first a suggestion to
limit the scope to trademark counterfeiting and copyright piracy in an
36

See TRIPS art. 51 (only mentioning importation of counterfeit trademark or pirated
copyright goods as subject to border measures).
37
See Anti-Counterfeiting Trade Agreement: Informal Predecisional/Deliberative
Draft,
Jan.
18,
2010,
art.
2.1,
available
at
http://www.laquadrature.net/files/201001_acta.pdf; ACTA Text–Apr. 2010, supra note 9
art. 2.1 (making no mention of the scope of intellectual property rights covered by the
Article on civil enforcement measures).
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August draft. But other parties, particularly the EU, promoted the use of
ACTA to broaden the scope of international enforcement mandates to all
intellectual property rights covered by TRIPS, including, especially, patents
and geographic indicators.
The final draft of ACTA permits countries to exclude patents and
undisclosed information from the scope of the civil enforcement section.
This change from earlier leaked drafts significantly reduces some negative
impacts on access to medicines.38 However, it is important to note that the
inclusion of patents and data protection within ACTA’s enforcement
mandates remains the default position. The provision that a country “may
exclude” suggests that such exclusion should be the exception rather than
the rule.39 This language may thus encourage countries to apply the ACTA
civil enforcement provisions to patents and data exclusivity, and could be
used by trading partners for this purpose.40 Allowing Parties to expand the
focus of ACTA to patents or data protection can directly endanger the
legitimate trade of generic products.41
B. Chapter II, Section 2, Article 8, 1 – INJUNCTIONS
Each Party shall provide that, in civil judicial proceedings
concerning the enforcement of intellectual property rights, its
judicial authorities have the authority to issue an order against a
party to desist from an infringement, and inter alia, an order to that
party or, where appropriate, to a third party over whom the
relevant judicial authority exercises jurisdiction, to prevent goods
that involve the infringement of an intellectual property right from
entering into the channels of commerce.

1. Related TRIPS Provision

38

See ACTA Assessment at 60.
See Baker, supra note 27, at 594 (noting that the permissive nature of ACTA’s
exclusion of patents and data protection from the section on civil enforcement is ineffective
unless a “a country actively chooses to exclude”).
40
See id. at 594 (remarking on the possibility of subtle pressure as a result of the
presumptive inclusion of patents and data protection in the scope of civil enforcement, and
more active pressure from influential trade partners with the aim of maintaining the
inclusion).
41
Public Comment, Generic Pharma. Assoc., Comments of the Generic
Pharmaceutical Association on the Anti-Counterfeiting Trade Agreement 2 (Feb. 15,
2011), http://www.regulations.gov/#!documentDetail;D=USTR-2010-0014-0113.
39
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TRIPS – Sec. 2, Art. 44(1) – Civil and Administrative Procedures and
Remedies – Injunctions
● The judicial authorities shall have the authority to order a party to
desist from an infringement, inter alia to prevent the entry into the
channels of commerce in their jurisdiction of imported goods that
involve the infringement of an intellectual property right,
immediately after customs clearance of such goods. Members are
not obliged to accord such authority in respect of protected subject
matter acquired or ordered by a person prior to knowing or having
reasonable grounds to know that dealing in such subject matter
would entail the infringement of an intellectual property right.
2. Analysis
ACTA expands injunction requirements for member countries in
important respects. TRIPS requires that member countries have authority to
prevent intellectual property infringing “imported” goods from “the
channels of commerce in their jurisdiction.”42 The provision is thus limited
to goods entering the market of the country applying the procedure; it does
not apply to exports or in-transit goods. In ACTA, these limitations are
removed.43 The words “imported” and “in their jurisdiction” are absent,
leaving a duty to authorize injunctions to halt the flow of infringing goods
into any commerce, whether or not such commerce is in the country’s
jurisdiction.
Injunctions are a useful tool for reducing the prevalence of counterfeit
goods in a market, but like all tools, they can be abused.44 When applied to
international trade, they can prevent market entry.45 By mandating
injunctions for goods not being imported into the country and not destined
for that country’s markets, ACTA’s injunction provisions raise the
possibility of aforementioned “Dutch seizure” type problems – i.e. where
the authorities in one country issue injunctions preventing goods from
entering commerce in a third country without that third country’s officials
ever passing on whether the item would infringe its own laws.46
42

See TRIPS art. 44:1 (only mentioning importation of counterfeit trademark or
pirated copyright goods as subject to border measures).
43
See ACTA Text–Dec. 3, 2010, supra note 3, art. 8:1 (applying injunctive measures
to all infringing goods that might enter into the channels of commerce, with no limitation to
imports).
44
See ACTA Assessment at 61.
45
Id. at 60.
46
See Weatherall, supra note 16, at 249 (explaining the danger of “in-transit”
enforcement as the “extraterritorial application of the transit country’s” intellectual
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The ACTA language also eliminates the second part of the TRIPS
injunction language providing a safeguard not obliging members to
authorize injunctions in the event that a person does not have “reasonable
grounds to know that dealing in such subject matter would entail the
infringement of an intellectual property right.”47 Since TRIPS safeguards
are included for other provisions of ACTA, the exclusion of an important
safeguard here raises troubling interpretative questions about the
negotiators’ intent.
Also of great concern is the extension of mandatory injunction authority
against third parties. In the realm of the generics trade, these third-parties
include active pharmaceutical ingredient (“API”) suppliers, which provide
materials for the manufacture of pharmaceuticals, and transporters and
registrants involved in the commercial and legal aspects of bringing generic
pharmaceuticals to market.48 The application of injunctive and provisional
measures to third parties associated with drugs alleged to have infringed on
a patent or trademark may deter their involvement in the generics trade.
C. Chapter II, Section 2, Article 9, 1 – DAMAGES
Each Party shall provide that, in civil judicial proceedings
concerning the enforcement of intellectual property rights, its
judicial authorities have the authority to order the infringer who,
knowingly or with reasonable grounds to know, engaged in
infringing activity to pay the right holder damages adequate to
compensate for the injury the right holder has suffered as a result
of the infringement. In determining the amount of damages for
infringement of intellectual property rights, a Party’s judicial
authorities shall have the authority to consider, inter alia, any
legitimate measure of value the right holder submits, which may
include lost profits, the value of the infringed goods or services
measured by the market price, or the suggested retail price.

1. Related TRIPS Provisions
TRIPS Sec. 2, Art. 45(1) – Civil and Administrative Procedures and
Remedies – Damages
property rights).
47
See TRIPS art. 44:1.
48
Baker, supra note 27, at 581.
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●

The judicial authorities shall have the authority to order the infringer
to pay the right holder damages adequate to compensate for the
injury the right holder has suffered because of an infringement of
that person’s intellectual property right by an infringer who
knowingly, or with reasonable grounds to know, engaged in
infringing activity.

2. Analysis
The ACTA provision on damages expands TRIPS requirements by
delineating specific measures of damages that each member’s authorities
“shall consider.”49 The measures suggested by ACTA, including lost profits
of the rights holder and the “market price” or “suggested retail price”
“submitted by the right holder,” are highly inappropriate for developing
countries as they reinforce exclusionary pricing incentives.
It is recognized that intellectual property monopolies on needed
medicines in middle-income countries promote profit-maximizing pricing to
the elite segment of the population (e.g. top 10% or so of the economy).50
To promote access to affordable medications, developing countries must
adopt policies that require or incentivize intellectual property holders to
allow competition or set prices much lower than the profit maximizing
level.51 Setting damages for infringements of patents or other intellectual
property on medicines in developing countries at “lost profit” or the retail
price demanded by the supplier works directly counter to this essential
public health policy. Such measures would routinely overcompensate brand
name drug suppliers for socially harmful pricing strategies and over-deter
generics from legitimately entering markets.
This provision can be contrasted with measures of damages that would
flow from access to medicines concerns and human rights. For example,
many patent laws, especially in developing countries, require rights holders
to work the invention by serving the entire market on reasonable terms.52
49

Compare TRIPS art. 45 (suggesting methods of determining damages that judicial
authorities may authorize), with ACTA Text–Dec. 3, 2010, supra note 3, arts. 9:3, 9:3(b)
n.3 (including the TRIPS suggestions plus recommended formulas for calculating
damages).
50
See Sean Flynn et al., An Economic Justification of Open Access to Essential
Medicine Patents in Developing Countries, 37 J.L. MED. & ETHICS 184, 190 (2009)
(indicating that a drug monopolist in developing with high levels of inequality will
maximize revenue by selling at a high price with only the rich able to pay).
51
See id. at 191 (demonstrating that the grant of open licenses on patents for essential
medicines to permit competition allows markets to decrease prices toward the marginal
cost of producing the drugs).
52
See id. at 192 (describing the order by the South African Competition Commission
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An incentive to meet working requirements could be furthered by setting
infringement damages at very low levels where the infringer supplies
markets left unserved by the intellectual property holder. Such a rule would
reduce risk and promote entry for generic producers seeking to serve poor
communities and severe needs. ACTA works counter to this goal.
D. Chapter II, Section 2, Article 9, 2 – DAMAGES
At least in cases of copyright or related rights infringement and
trademark counterfeiting, each Party shall provide that, in civil
judicial proceedings, its judicial authorities have the authority to
order the infringer to pay the right holder the infringer’s profits
that are attributable to the infringement. A Party may presume
those profits to be the amount of damages referred to in
paragraph 1.

1. Related TRIPS Provisions
TRIPS Part III, Sec. 2, Art. 45(2) – Civil and Administrative Procedures
and Remedies – Damages
● The judicial authorities shall also have the authority to order the
infringer to pay the right holder expenses, which may include
appropriate attorney's fees. In appropriate cases, Members may
authorize the judicial authorities to order recovery of profits and/or
payment of pre-established damages even where the infringer did
not knowingly, or with reasonable grounds to know, engage in
infringing activity.
2. Analysis
ACTA removes the internal safeguard from the TRIPS requirement on
restitution of profits that such awards only be in “appropriate cases.”53 It is
unclear how the removal of this internal safeguard will be interpreted. One
possibility is that it could prohibit appropriate exceptions to damages
measures, such as the standard discussed above making damages
that authorized any person seeking to manufacture generic versions of certain patented
medicines in exchange for a “reasonable royalty”) (quoting Media Release, South Africa
Competition Commission, Competition Commission Finds Pharmaceutical Firms in
Contravention
of
the
Competition
Act
(October
16,
2003),
http://www.wcl.american.edu/pijip/documents/MediaRelease.doc).
53
Compare TRIPS art. 45, with ACTA Text–Dec. 3, 2010, supra note 3, art. 9(2).
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determinations in reference to whether the infringer is supplying markets
left unserved by the infringer. This section also appears intended to expand
the use of damage measures in Article 9(2), identified as problematic for
access to medicines concerns above.
E. Chapter II, Section 2, Article 9, 3(b), fn. 3: DAMAGES
The presumptions referred to in subparagraph 3(b) may include
a presumption that the amount of damages is: (i) the quantity of
the goods infringing the right holder’s intellectual property
right in question and actually assigned to third persons,
multiplied by the amount of profit per unit of goods which
would have been sold by the right holder if there had not been
the act of infringement; or (ii) a reasonable royalty; or (iii) a
lump sum on the basis of elements such as at least the amount of
royalties or fees which would have been due if the infringer had
requested authorization to use the intellectual property right in
question.

1. Related TRIPS Provisions
TRIPS Sec. 2, Art. 45(2) – Civil and Administrative Procedures and
Remedies – Damages
● The judicial authorities shall also have the authority to order the
infringer to pay the right holder expenses, which may include
appropriate attorney's fees. In appropriate cases, Members may
authorize the judicial authorities to order recovery of profits and/or
payment of pre-established damages even where the infringer did
not knowingly, or with reasonable grounds to know, engage in
infringing activity.
2. Analysis
ACTA encourages damages to be calculated based on “the quantity of
the goods infringing the right holder’s intellectual property right . . .
multiplied by the amount of profit per unit of goods which would have been
sold by the right holder . . .” 54 This could be a very invidious standard in
many access to medicines cases. For example, pharmaceutical companies
might serve high-risk/low-income countries – e.g. those with a GDP per
54

ACTA Text–Dec. 3, 2010, supra note 3, art. 9:3(b) n.3.
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capita below one dollar a day and an AIDS rate of 20 percent of the adult
population – with a branded AIDS drug at a price of $12,000 per year. If an
Indian supplier entered such a market and offered a generic drug at a price
of less than $90 a year, but did so with a label that was found to have
technically infringed on the trademark of the rights owner, what amount
damages should be awarded? Multiplying the number of highly demanded
generic units by the branded drug’s asking price would result in a damage
award higher than the company could have ever received through marketing
its own product. Such exorbitant damage awards go beyond mere deterrence
of technical infringement and can instead prevent a generic manufacturer
from entering an at-risk market entirely.
It is noteworthy that the options for damage calculations include one
that is fairly protective of access to medicines concerns. A damage
calculation based on “(ii) a reasonable royalty”55 linked to a percentage of
the generic price can avoid the problems identified with retail or “market”
price valuations. In the case above, the damage award here would be a
reasonable percentage of the $90 generic price, rather the difference
between the $90 sale and the $12,000 expectation of the brand supplier.
However, the fact that a legitimate generics manufacturer might be subject
to trademark counterfeiting damages in the first place remains the area of
greatest concern.
As in other areas of ACTA, the problem is not that this provision
mandates the worst possible practices, but it does appear to encourage them.
If the agreement is adopted, it will be important for technical assistance to
be directed at explaining the full range of interpretive options available and
encouraging developing countries to adopt those most protective of access
to medicine concerns.
F. Chapter II, Section 2, Article 11 – INFORMATION RELATED TO
INFRINGEMENT
Without prejudice to its law governing privilege, the protection
of confidentiality of information sources, or the processing of
personal data, each Party shall provide that, in civil judicial
proceedings concerning the enforcement of intellectual property
rights, its judicial authorities have the authority, upon a justified
request of the right holder, to order the infringer or, in the
alternative, the alleged infringer, to provide to the right holder
or to the judicial authorities, at least for the purpose of
55

Id.
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collecting evidence, relevant information as provided for in its
applicable laws and regulations that the infringer or alleged
infringer possesses or controls. Such information may include
information regarding any person involved in any aspect of the
infringement or alleged infringement and regarding the means
of production or the channels of distribution of the infringing or
allegedly infringing goods or services, including the
identification of third persons alleged to be involved in the
production and distribution of such goods or services and of
their channels of distribution.

1. Related TRIPS Provisions
TRIPS Sec. 2, Art. 47 – Civil and Administrative Procedures and Remedies
– Right of Information
● Members may provide that the judicial authorities shall have the
authority, unless this would be out of proportion to the seriousness
of the infringement, to order the infringer to inform the right holder
of the identity of third persons involved in the production and
distribution of the infringing goods or services and of their channels
of distribution.
2. Analysis
ACTA dramatically expands requirements to authorize disclosure to
rights holders of information on alleged infringers. The ACTA language
repeats the TRIPS requirement that members have a mechanism to order
proven infringers to turn over information to “identity of third persons
involved in the production and distribution of the infringing goods or
services.”56 But ACTA expands this duty to:
57
● include “alleged” infringers,
● remove the internal safeguard that countries need not grant such
authority if it “would be out of proportion to the seriousness of the
infringement,”58
● extend to a much broader range of information, including that
“regarding any person involved in any aspect of the infringement or
56

See TRIPS art. 47; ACTA Text–Dec. 3, 2010, supra note 3, art. 11.
ACTA Text–Dec. 3, 2010, supra note 3, art. 11.
58
Compare TRIPS art. 47, with ACTA Text–Dec. 3, 2010, supra note 3, art. 11
(reducing the safeguard to a “justified request of the right holder”).
57
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alleged infringement,” and “regarding the means of production or
the channels of distribution of the infringing or allegedly infringing
goods or services”59

In deference to the privacy protections existing in some countries,
ACTA makes this provision subject to members’ “law governing privilege,
the protection of confidentiality of information sources, or the processing of
personal data.”60 But for countries without such protections, invasions of
privacy and business confidentiality could be particularly invidious in the
implementation of this section.
In practical effect, the provision could be used by right holders to
discover details on distribution chains of generic companies and mount
aggressive and expensive litigation against suppliers and intermediaries that
deal with generic producers of allegedly infringing products. Applied to
patents, the provision could be particularly troublesome since the actual
determination of patent infringement is quite technical. But even applied to
trademark infringement this provision is very concerning, since generic
products often use labels, colors and other identifiers that are somewhat
similar to brand products – to create consumer comfort with brand
switching and maintain bioequivalence – while attempting to steer free of
trademark violations. In this context, a great range of generic products could
be subject to colorable allegations of trademark infringement even if the end
products do not actually infringe.61 Beyond expensive litigation, the
information provisions could lead to harassment of members of their
competitor’s distribution chains by right holders. These provisions, in
conjunction with those concerning third-party enforcement, can allow for
the destruction of generic medicines found to be infringing on a trademark
(or patent if a regime permits). Intermediaries might also be subject to
heightened threats of injunctions, provisional measures, and criminal
sanctions.62

59

ACTA Text–Dec. 3, 2010, supra note 3, art. 11.
Id.
61
See generally Sean Flynn, Counterfeit Versus “Confusingly Similar” Products,
PIJIP BLOG (May 7, 2010), http://www.wcl.american.edu/pijip/go/pijip05072010
(analyzing the ambiguity present in determining whether a good is confusingly similar,
counterfeit, or neither).
62
See Baker, supra note 27, at 595 (explaining how an innocent third party supplier or
distributor could be subject to criminal sanctions as a result of ACTA’s aiding and abetting
provision).
60
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G. Chapter II, Section 2, Article 12, 1(a) – PROVISIONAL MEASURES
Each Party shall provide that its judicial authorities have
the authority to order prompt and effective provisional
measures:
(a)
against a party or, where appropriate, a third
party over whom the relevant judicial authority
exercises jurisdiction, to prevent an infringement
of any intellectual property right from occurring,
and in particular, to prevent goods that involve
the infringement of an intellectual property right
from entering into the channels of commerce;

1. Related TRIPS Provisions
TRIPS Sec. 3, Art. 50(1) – Provisional Measures
● The judicial authorities shall have the authority to order prompt and
effective provisional measures: (a) to prevent an infringement of any
intellectual property right from occurring, and in particular to
prevent the entry into the channels of commerce in their jurisdiction
of goods, including imported goods immediately after customs
clearance; (b) to preserve relevant evidence in regard to the alleged
infringement.
2. Analysis
ACTA and TRIPS both provide for provisional measures, but ACTA
expands the obligation by requiring authorities to apply provisional
measures against third parties where appropriate.63 ACTA also eliminates
the internal qualifier that provisional measures enjoining entry into streams
of commerce be limited to such commerce “in their jurisdiction.”64 Like
Article 8, Injunctions, above, this expansion raises the possibility of “Dutch
seizure” type actions of one country to halt the shipments of medicines or
other goods to a third country, even with no determination that the good
would violate the intellectual property laws in that third country. A single
63

Compare TRIPS art. 50:1, with ACTA Text–Dec. 3, 2010, supra note 3, art. 12:1(a)
(expanding the reach of provisional measures to third parties).
64
Compare TRIPS art. 50.1(a) (stating that judicial authorities have the authority to
order provisional measures to prevent infringing goods from entry into the channels of
commerce “in their jurisdiction”), with ACTA Text–Dec. 3, 2010, supra note 3, art. 12:1(a)
(including reference to the channels of commerce, but omitting the “in their jurisdiction”
language).
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intermediary in a generics chain can have infringement alleged and related
third parties can have provisional measures enacted against them. These
provisional measures might require generic industry intermediaries,
including active pharmaceutical ingredient manufacturers and shippers, to
cease business with generics firms to prevent “future” infringement –
something that might cause irreparable harm to the generics market.65
The ACTA text fails to incorporate other sections of TRIPS Article 50
that reflect a more balanced concern for those subject to seizures. ACTA
fails to incorporate, for example, Article 50(6) requiring provisional
measures to be revoked “if proceedings leading to a decision on the merits
of the case are not initiated within a reasonable period,” or 50(7) mandating
“appropriate compensation” to the defendant of baseless suits “for any
injury caused by these measures.”
As in other areas of ACTA, the scope of the provision applying “at
least” to trademark and copyright issues suggests a preference default for
applying the standards to patents and other disparate intellectual property
doctrines as well. As discussed throughout this report, the application of
remedies and injunctions to patent issues without adequate hearings and
expert inquiry is inadvisable and should not be promoted even through softlaw encouragements.
H. Chapter II, Section 2, Article 12, 3 – PROVISIONAL MEASURES
At least in cases of copyright or related rights infringement and
trademark counterfeiting, each Party shall provide that, in civil
judicial proceedings, its judicial authorities have the authority to
order the seizure or other taking into custody of suspect goods,
and of materials and implements relevant to the act of
infringement, and, at least for trademark counterfeiting,
documentary evidence, either originals or copies thereof,
relevant to the infringement.

1. Related TRIPS Provisions

65

See Baker, supra note 27, at 581 (predicting that necessary API suppliers, shippers,
and funders could be deterred from involvement with generic producers); Peter
Maybarduk, ACTA and Public Health 10 (Prog. on Info. Justice and Intellectual Prop.
Working
Paper
No.
9,
2010),
available
at
http://digitalcommons.wcl.american.edu/research/9/ (describing the chilling effect the
uncertain reach of injunctive measures could have on the generics market).
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TRIPS Part III, Sec. 3, Art. 50(1)
● The judicial authorities shall have the authority to order prompt and
effective provisional measures: (a) to prevent an infringement of any
intellectual property right from occurring, and in particular to
prevent the entry into the channels of commerce in their jurisdiction
of goods, including imported goods immediately after customs
clearance; (b) to preserve relevant evidence in regard to the alleged
infringement.
2. Analysis
The final draft expands on TRIPS art. 50 to explicitly mandate
authorization of seizures of “suspect” goods in the copyright/trademarkcounterfeiting context during civil judicial proceedings.66 Under this new
standard, all goods suspected of infringement are subject to seizure in
addition to the implements of their creation during proceedings on the
merits. As a result, shipments of generic medicine related to those alleged to
have infringed can be seized or their manufacture prevented with the seizure
of necessary manufacturing apparatus. There is no restriction in this
provision that goods seized be destined for a market within the jurisdiction
of the enforcing country, Thus, this provision may be used to promote
“Dutch seizure” type actions of one country to halt the shipments of
medicines or other goods to a third country, even with no determination that
the good would violate the intellectual property laws in that third country.
I. Chapter II, Section 3, Article 13, fn. 6, SCOPE OF BORDER
MEASURES
The Parties agree that patents and protection of undisclosed
information do not fall within the scope of this Section.

1. Related TRIPS Provisions
TRIPS Part III, Sec. 4, Art. 51 – SPECIAL REQUIREMENTS RELATED
TO BORDER MEASURES – SUSPENSION OF RELEASE BY
CUSTOMS AUTHORITIES [No limitations as to the scope of border
measures.]
66

Compare TRIPS art. 50:1, with ACTA Text–Dec. 3, 2010, supra note 3, art. 12:3
(“[E]ach Party shall provide that, in civil judicial proceedings, its judicial authorities have
the authority to order the seizure or other taking into custody of suspect goods . . .”).
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●

Members shall, in conformity with the provisions set out below,
adopt procedures to enable a right holder, who has valid grounds for
suspecting that the importation of counterfeit trademark or pirated
copyright goods may take place, to lodge an application in writing
with competent authorities, administrative or judicial, for the
suspension by the customs authorities of the release into free
circulation of such goods. Members may enable such an application
to be made in respect of goods which involve other infringements of
intellectual property rights, provided that the requirements of this
Section are met. Members may also provide for corresponding
procedures concerning the suspension by the customs authorities of
the release of infringing goods destined for exportation from their
territories.

2. Analysis
Border measures are methods by which customs authorities of member
nations can seize goods suspected of infringement of intellectual property
rights.67 In an effort to stave off complaints about ACTA from public health
advocates, ACTA’s provisions on border measures have been made
inapplicable to patents.68 This is a positive, but unfortunately limited
change.69 ACTA still contains a dramatic expansion of border measures
requirements to all intellectual property rights in TRIPS not within this
narrow exception.
ACTA’s expansion of border measures beyond “counterfeit trademark
or pirated copyright goods” will notably include requirements that countries
authorize seizures of suspected “confusingly similar” trademarks.70 “The
inclusion of civil trademark claims in ACTA’s border measures creates
67

See Weatherall, supra note 16, at 244 (defining border measures as “procedures for
the detention, by customs authorities, of goods suspected of infringing intellectual property
rights . . . .”).
68
See ACTA Text–Dec. 3, 2010, supra note 3, art. 13 n.6 (stating “[t]he Parties agree
that patents and protection of undisclosed information do not fall within the scope of this
section”).
69
The language of exclusion of patents in the Border Measures chapter is stronger than
in Civil Enforcement. Compare ACTA Text–Dec. 3, 2010, supra note 3, art. 7 n.2
(members “may exclude”), with id. art. 13 n.6 (“patents . . . do not fall within the scope” of
border measures). But cf. Baker, supra note 27, at 593 (citing Council Regulation
1383/2003, 2003 O.J. (L 196) 7 (EC)) (“Unfortunately, this exclusion does not prevent
ACTA members from unilaterally adopting patent-related border measures such as those
currently codified in EC 1383/2003 . . . .”).
70
See ACTA Assessment at 62 (noting that ACTA’s treatment of similar or confusing
trademarks could lead to issues with the generic trade).
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risks for access to medicines similar to those raised by patents.”71
Unlike counterfeiting, in which trademarks must be willfully identical to
the original mark, determination of infringing marks under the confusingly
similar doctrine are quite fact and law intensive. And there is existing
evidence of the wrongful use of this standard to delay shipments of needed
medicines in Europe. German authorities used this ground to wrongfully
halt a generic shipment of amoxicillin, the INN name, because the officials
reasoned that it was confusingly similar to a trademarked name:
“Amoxil.”72 ACTA exports the doctrinal basis of these EU seizures to all
member countries, raising the risk of similar seizures of legitimate generic
medicines elsewhere.73
Aggressive enforcement of a right to preempt “similar” marks can also
conflict with public health policy.74 Such policy may promote the use of
similar colors, shapes and names for branded and generic registered
medicines to promote generic substitution and avoid patient confusion and
prescription errors.75
J. Chapter II, Section 3, Article 16 – BORDER MEASURES
1. Each Party shall adopt or maintain procedures with
respect to import and export shipments under which:
(a) its customs authorities may act upon their own
initiative to suspend the release of suspect goods; and
(b) where appropriate, a right holder may request its
competent authorities to suspend the release of suspect
goods.
2. A Party may adopt or maintain procedures with respect to
suspect in-transit goods or in other situations where the
goods are under customs control under which:
(a) its customs authorities may act upon their own
initiative to suspend the release of, or to detain, suspect
goods; and
(b) where appropriate, a right holder may request its

71

Maybarduk, supra note 65, at 27.
See Press Release, Health Action International, supra note 18.
73
See ACTA Assessment at 62.
74
See id. at 61.
75
See generally Flynn, Confusingly Similar, supra note 61.
72

WWW.GREENS-EFA.EU

27

The Greens | European Free Alliance
competent authorities to suspend the release of, or to
detain, suspect goods.

1. Related TRIPS Provisions
TRIPS Sec. 4, Art. 58 – Special Requirements Related to Border Measures–
Ex Officio Action
● Where Members require competent authorities to act upon their own
initiative and to suspend the release of goods in respect of which
they have acquired prima facie evidence that an intellectual property
right is being infringed: (a) the competent authorities may at any
time seek from the right holder any information that may assist them
to exercise these powers; (b) the importer and the right holder shall
be promptly notified of the suspension. Where the importer has
lodged an appeal against the suspension with the competent
authorities, the suspension shall be subject to the conditions, mutatis
mutandis, set out at Article 55; (c) Members shall only exempt both
public authorities and officials from liability to appropriate remedial
measures where actions are taken or intended in good faith.
fn. 13
● It is understood that there shall be no obligation to apply such
procedures to imports of goods put on the market in another country
by or with the consent of the right holder, or to goods in transit.
2. Analysis
There is no requirement in TRIPS that members grant ex officio border
seizure authority.76 Where members do give such authorization for imported
goods, such seizures require prima facie evidence, must be followed by
prompt notification of the importer, and, by referencing Art. 55, must be
released within 10 working days if the right holder does not initiate a
proceeding on the merits.77 There is “no obligation to apply” TRIPS border
provisions to in-transit procedures.78
ACTA escalates border seizure requirements while reducing safeguards.
ACTA mandates ex officio seizures, extends the scope of requirements to
include exports, and makes no mention of a prima facie evidence
76

See TRIPS art. 58 (addressing Member states where competent authorities are
required to act upon their own initiative to suspend the release of suspect goods).
77
Id. arts. 58, 54, 55.
78
Id. art. 51 n.13.
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requirement or limited duration of the suspension pending a determination
on the merits.79 ACTA leaves the application of border seizure measures to
in-transit shipments permissible, but does so with language encourages the
practice.80
These provisions raise the potential for abuse and wrongful detention of
legitimate products. Infringement claims based on similar marks, trademark
dilution, unfair advantage or damage to reputation are fertile ground for
abuse of in-transit enforcement measures.81 Rights holders might use border
measures to harass competitors producing legitimate generic
pharmaceuticals, relying on unprepared and unqualified customs authorities
to determine whether rights holder claims are reasonable or unfounded.82
In-transit enforcement further complicates the potential for abuse or
mistake.83

K. Chapter II, Section 3, Article 17, 1 – APPLICATION BY THE RIGHT
HOLDER
Each Party shall provide that its competent authorities require a
right holder that requests the procedures described in
subparagraphs 1(b) and 2(b) of Article 16 (Border Measures) to
provide adequate evidence to satisfy the competent authorities that,
under the law of the Party providing the procedures, there is prima
facie an infringement of the right holder's intellectual property
right, and to supply sufficient information that may reasonably be
expected to be within the right holder’s knowledge to make the
suspect goods reasonably recognizable by the competent authorities.
The requirement to provide sufficient information shall not
unreasonably deter recourse to the procedures described in
subparagraphs 1(b) and 2(b) of Article 16 (Border Measures).

79

See ACTA Text–Dec. 3, 2010, supra note 3, art. 16:1 (stating that Parties “shall
adopt” measures where customs authorities may act on their own initiative to seize goods
without any reference to evidence requirements or a duration of the seizure).
80
See id. art. 16:2 (stating that Parties “may adopt” procedures as opposed to having
no obligation).
81
See ACTA Assessment at 61.
82
Maybarduk, supra note 65, at 17.
83
See Weatherall, supra note 16, at 249 (“(1) the law of the country in which the
customs procedure is invoked; (2) the law of the origin country; (3) the law of the
destination country; or (4) by some combination (requiring, for example, infringement
according to local and foreign law) . . . .”).
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1. Related TRIPS Provisions
TRIPS Sec. 4, Art. 52 – Special Requirements Related to Border Measures
– Application
● Any right holder initiating the procedures under Article 51 shall be
required to provide adequate evidence to satisfy the competent
authorities that, under the laws of the country of importation, there is
prima facie an infringement of the right holder’s intellectual
property right and to supply a sufficiently detailed description of the
goods to make them readily recognizable by the customs authorities.
The competent authorities shall inform the applicant within a
reasonable period whether they have accepted the application and,
where determined by the competent authorities, the period for which
the customs authorities will take action.
2. Analysis
ACTA puts in place a streamlined system of border control that caters to
rights holders while offering minimal safeguards or recourse for the
wrongly accused. ACTA allows countries to rely on customs officials to
perform complex adjudications on IPR issues at the border, rather than
requiring judicial review,84 and adds to TRIPS requirements a duty to
ensure that evidence requirements for suspensions “shall not unreasonably
deter recourse to the procedures.”85 On the other side, ACTA fails to
mention any concrete duration or required action for continued
suspension,86 omits requirements to indemnify importers for wrongful
84

ACTA defines “competent authorities” as including the “appropriate judicial,
administrative, or law enforcement authorities . . .” ACTA Text–Dec. 3, 2010, supra note
3, art. 5(c). Given that “judicial authorities” are specifically mentioned throughout the
earlier sections on provisional measures, it is striking that Parties are instead encouraged to
use “competent authorities” with respect to border measures. See id. art. 19 (requiring that
parties adopt procedures for its competent authorities to determine whether an infringement
has occurred).
85
ACTA Text–Dec. 3, 2010, supra note 3, art. 17:1. TRIPS contains similar safeguard
language for rights holders in other provisions. See TRIPS arts. 54-56 (providing for
safeguards for the importer, including prompt notice of seizure, a ten working day period
for rights holders to begin proceedings on the merits and subsequent review, and the power
for authorities to order rights holders to indemnify importers following wrongful or poorly
conducted detention).
86
ACTA does not repeat the TRIPS provision for the release of suspect goods if a
proceeding on the merits has not been initiated within ten working days. Art. 19.
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detention,87 and fails to require notice to importers whose goods have been
seized.88
Legitimate generic medicines have already been shown to be vulnerable
to overzealous customs authorities and overbroad infringement
definitions,89 and ACTA’s distinctly pro-rights holder border measure
procedures exacerbate that danger. Generic medicines can be detained for a
“reasonable” period at the request of rights holders with minimal evidence,
by customs authorities with little experience in complex issues of trademark
infringement. As ACTA has no requirement for notifying the manufacturers
or importers, those subject to seizures will be less able to challenge
wrongful detentions of legitimate generics. ACTA’s additional failure to
insist on adjudication on the merits by judicial authorities could result in
countries with less means allowing border authorities to make
determinations as to trademark infringement for those generics. These
factors combined can delay or preclude the arrival of necessary drugs in
countries with a serious need for affordable treatments.
L. Chapter II, Section 3, Article 17, 2 – MULTIPLE SHIPMENTS
Each Party shall provide for applications to suspend the release
of, or to detain, any suspect goods [7] under customs control in
its territory. A Party may provide for such applications to apply
to multiple shipments. A Party may provide that, at the request
of the right holder, the application to suspend the release of, or
to detain, suspect goods may apply to selected points of entry
and exit under customs control.

1. Related TRIPS Provisions
TRIPS Sec. 4 Article 51 – Special Requirements Related to Border
Measures – Suspension of Release by Customs Authorities
● Members shall, in conformity with the provisions set out below,
adopt procedures [13] to enable a right holder, who has valid
87

See id. art. 17:4, 18, 20 (making no mention of indemnification of the defendant in
the event of a faulty claim, despite mentioning abuse of procedures, assurance for the
defendant, and remedies).
88
See id. art. 17:3 (ensuring that the competent authorities inform the applicant of the
status of the application, without giving consideration to the defendant whose goods are
seized).
89
See supra note 16.
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grounds for suspecting that the importation of counterfeit trademark
or pirated copyright goods [14] may take place, to lodge an
application in writing with competent authorities, administrative or
judicial, for the suspension by the customs authorities of the release
into free circulation of such goods. Members may enable such an
application to be made in respect of goods which involve other
infringements of intellectual property rights, provided that the
requirements of this Section are met. Members may also provide for
corresponding procedures concerning the suspension by the customs
authorities of the release of infringing goods destined for exportation
from their territories.

2. Analysis
ACTA expands on TRIPS border measures by authorizing applications
by rights holders for seizure of multiple shipments.90 This does not appear
to be a change in the underlying legal landscape – TRIPS did not prohibit
such applications and ACTA is permissive in this regard. But including the
concept in ACTA may encourage more countries to adopt procedures
applicable to multiple shipments. The potential problem for access to
medicines concerns is the increased risk of arbitrary seizures of products
that may follow from broad authorizations of border interdiction.
M. Chapter II, Section 3, Article 20, 1 – DESTRUCTION OF GOODS
Each Party shall provide that its competent authorities have the
authority to order the destruction of goods following a
determination referred to in Article 19 (Determination as to
Infringement) that the goods are infringing. In cases where such
goods are not destroyed, each Party shall ensure that, except in
exceptional circumstances, such goods are disposed of outside the
channels of commerce in such a manner as to avoid any harm to the
right holder.

1. Related TRIPS Provisions
TRIPS Sec. 4, Art. 46. Other Remedies
● In order to create an effective deterrent to infringement, the judicial
authorities shall have the authority to order that goods that they have
90

See ACTA Text–Dec. 3, 2010, supra note 3, art. 17:2.
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found to be infringing be, without compensation of any sort,
disposed of outside the channels of commerce in such a manner as
to avoid any harm caused to the right holder, or, unless this would
be contrary to existing constitutional requirements, destroyed. The
judicial authorities shall also have the authority to order that
materials and implements the predominant use of which has been in
the creation of the infringing goods be, without compensation of any
sort, disposed of outside the channels of commerce in such a manner
as to minimize the risks of further infringements. In considering
such requests, the need for proportionality between the seriousness
of the infringement and the remedies ordered as well as the interests
of third parties shall be taken into account. In regard to counterfeit
trademark goods, the simple removal of the trademark unlawfully
affixed shall not be sufficient, other than in exceptional cases, to
permit release of the goods into the channels of commerce.

2. Analysis
ACTA requires that, “except in exceptional circumstances,” all
infringing goods be “disposed of outside the channels of commerce.”91 The
language in ACTA removes a key TRIPS safeguard, that “[i]n considering
such requests, the need for proportionality between the seriousness of the
infringement and the remedies ordered as well as the interests of third
parties shall be taken into account.” ACTA could be interpreted to require
that, for example, absent “exceptional circumstances,” a medicine found to
have a minor trademark infringement on a label be destroyed rather than relabeled and re-sold. ACTA also removes mention of a safeguard for the
accused present in TRIPS art. 59: the “right of the defendant to seek review
by judicial authority” of any decision to dispose of infringing goods.92
N. Chapter II, Section
INFORMATION

3,

Article

22(a)

–

DISCLOSURE

OF

a Party may authorize its competent authorities to provide a
right holder with information about specific shipments of goods,
including the description and quantity of the goods, to assist in
the detection of infringing goods;

91

See ACTA Text–Dec. 3, 2010, supra note 3, art. 25:3.
Compare TRIPS art. 59, with ACTA Text–Dec. 3, 2010, supra note 3, arts. 19, 25:3
(failing to mention mechanisms for the appeal or review of determinations of infringement
and resulting orders of destruction).
92
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1. Related TRIPS Provisions
TRIPS Sec. 4, Art. 57 – Special Requirements Related to Border Measures
– Right of Inspection and Information
● Without prejudice to the protection of confidential information,
Members shall provide the competent authorities the authority to
give the right holder sufficient opportunity to have any goods
detained by the customs authorities inspected in order to substantiate
the right holder’s claims. The competent authorities shall also have
authority to give the importer an equivalent opportunity to have any
such goods inspected. Where a positive determination has been
made on the merits of a case, Members may provide the competent
authorities the authority to inform the right holder of the names and
addresses of the consignor, the importer and the consignee and of
the quantity of the goods in question.
2. Analysis
TRIPS requires member countries to have the authority “to give the
right holder sufficient opportunity to have any goods detained by the
customs authorities inspected” to substantiate any claims of infringement.93
TRIPS includes a balancing provision giving the importer this same
opportunity.94 ACTA adds that members “may . . . provide a right holder
with information about specific shipments of goods.”95 There is nothing in
TRIPS that would appear counter to such authorization within a member
state and therefore this section does not appear to alter the legal background
rules. Nonetheless, its inclusion in ACTA may encourage countries to grant
such authorization. The new ACTA provision is notably one-sided – it
includes an information right for the rights holder, but no comparable right
or protection for the importer. This provision lends itself to abuse, as rights
holders can seek out legitimate or technically infringing shipments of
necessary generics and request for the detention of all of these shipments by
the low evidentiary standard set out in Article 17.
O. Chapter II, Section 4, Article 23 – CRIMINAL OFFENCES

93

TRIPS art. 57.
Id.
95
ACTA Text–Dec. 3, 2010, supra note 3, art. 22(a).
94
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1. Each Party shall provide for criminal procedures and
penalties to be applied at least in cases of wilful trademark
counterfeiting or copyright or related rights piracy on a
commercial scale.[9] For the purposes of this Section, acts
carried out on a commercial scale include at least those
carried out as commercial activities for direct or indirect
economic or commercial advantage.
[fn 9]

Each Party shall treat willful importation or exportation of
counterfeit trademark goods or pirated copyright goods on a
commercial scale as unlawful activities subject to criminal penalties
under this Article. A Party may comply with its obligation relating to
importation and exportation of counterfeit trademark goods or
pirated copyright goods by providing for distribution, sale or offer
for sale of such goods on a commercial scale as unlawful activities
subject to criminal penalties.

2. Each Party shall provide for criminal procedures and
penalties to be applied in cases of wilful importation and
domestic use, in the course of trade and on a commercial
scale, of labels or packaging:
(a) to which a mark has been applied without
authorization which is identical to, or cannot be
distinguished from, a trademark registered in its
territory; and
b) which are intended to be used in the course of trade on
goods or in relation to services which are identical to
goods or services for which such trademark is registered.

1. Related TRIPS Provisions
TRIPS Sec. 5, Art. 61 – Criminal Procedures
● Members shall provide for criminal procedures and penalties to be
applied at least in cases of wilful trademark counterfeiting or
copyright piracy on a commercial scale. Remedies available shall
include imprisonment and/or monetary fines sufficient to provide a
deterrent, consistently with the level of penalties applied for crimes
of a corresponding gravity. In appropriate cases, remedies available
shall also include the seizure, forfeiture and destruction of the
infringing goods and of any materials and implements the
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predominant use of which has been in the commission of the
offence. Members may provide for criminal procedures and
penalties to be applied in other cases of infringement of intellectual
property rights, in particular where they are committed wilfully and
on a commercial scale.

2. Analysis
ACTA expands the definition of criminal offences for trademark
infringement by shifting the intent standard. The TRIPS criminal standard
for trademark was limited to “willful trademark counterfeiting.”96 The most
logical reading of TRIPS is that the intent modifies counterfeiting – i.e.
criminal counterfeiting is the intentional creation or use of an unauthorized
identical mark. ACTA shifts the intent standard from the use of the mark to
the act of importation and use of the good. At least in plain language terms,
one could meet the ACTA definition of a crime by intentionally importing a
good with a counterfeit label, even if that person did not intentionally create
or use the counterfeit label itself; indeed even if it was unknown that the
label was counterfeit.97 This has the potential to greatly expand the number
of cases of trademark misuse that could be considered criminal, including
the use and trade in parallel imported goods.
The potential extension of ACTA to the regulation of parallel imports
puts it at odds with the European Parliament’s resolution on the proposed
“directive on criminal measures aimed at ensuring the enforcement of
intellectual property rights” (“IPRED2”). Under that resolution, member
states are prohibited from applying criminal sanctions to cases of the
“parallel importation of original goods which have been marketed with the
agreement of the right-holder in a country outside the European Union.”98
Parallel imports by definition carry the exact labeling as the original good.
If the rights holder succeeds in declaring the labels on such goods to be
counterfeit by virtue of their use in parallel imports without authorization of
the right holder, then the standard for criminalization under ACTA could be
met even without any intent to make or use the counterfeit label. The intent
to import the good would be sufficient to meet the criminality
96

TRIPS art. 61.
See ACTA Assessment at 62 (discussing the potential issues from confusingly
similar trademarks).
98
European Parliament legislative resolution of 25 April 2007 on the amended
proposal for a directive of the European Parliament and of the Council on criminal
measures aimed at ensuring the enforcement of intellectual property rights,
P6_TA(2007)0145, available at http://www.europarl.europa.eu/sides/getDoc.do?pubRef=//EP//TEXT+TA+P6-TA-2007-0145+0+DOC+XML+V0//EN&language=EN#BKMD-12
97
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requirement.99 ACTA’s Article on criminal measures for counterfeiting can
be interpreted in a similar vein, as they extend to cases of counterfeiting on
a commercial scale.100 This includes commercial activities carried out for
indirect commercial benefit.101 The European Parliament’s position is that
acts performed by private and not-for-profit purposes should be excluded
from the scope of enforcement directives in the European Union,
particularly IPRED2.102 ACTA would seem to contradict that position.
The resulting effect of both of these criminal offence provisions could
be the application of criminal measures for individuals or groups seeking to
save money by parallel importing of medicines. In the trademark
infringement case, criminal sanctions could result if the medicine labels are
unlicensed in the country of import. In the aforementioned example
involving counterfeit labels, criminal sanctions could attach because the
importers indirectly benefitted commercially – they paid less for the
imported drugs. No matter the textual basis for the alleged crime, the result
remains the same – that innocent parties seeking affordable medicines are
potentially subject to costly criminal prosecution.
The impact may extend to third parties who supply or work with generic
producers, thanks to a provision that ensures criminal liability for “aiding
and abetting.”103 “An innocent supplier for a producer, who later turned out
to be a willful counterfeiter, could suddenly be deemed a criminal offender
under Article 23.4 of ACTA.”104 Like the third party enforcement
provisions present in other portions of ACTA, this provision could deter
involvement in generic manufacturing by necessary partners, raise prices,
and hinder accessibility worldwide.
P. Chapter II, Section 4, Article 25, 1 – SEIZURE, FORFEITURE, AND
DESTRUCTION
With respect to the offences specified in paragraphs 1, 2, 3, and 4 of
Article 23 (Criminal Offences) for which a Party provides criminal
procedures and penalties, that Party shall provide that its
competent authorities have the authority to order the seizure of
suspected counterfeit trademark goods or pirated copyright goods,
99

See European Academics, supra note 11, ¶8.
See ACTA Text–Dec. 3, 2010, supra note 3, art. 23:1.
101
Id.
102
See ACTA Assessment at 62 (discussing the potential issues from confusingly
similar trademarks).
103
See ACTA Text–Dec. 3, 2010, supra note 3, art. 23:4.
104
Baker, supra note 27, at 595.
100

WWW.GREENS-EFA.EU

37

The Greens | European Free Alliance
any related materials and implements used in the commission of the
alleged offence, documentary evidence relevant to the alleged
offence, and the assets derived from, or obtained directly or
indirectly through, the alleged infringing activity.

1. Related TRIPS Provisions
TRIPS Part III, Sec. 5, Art. 51
● Members shall provide for criminal procedures and penalties to be
applied at least in cases of wilful trademark counterfeiting or
copyright piracy on a commercial scale. Remedies available shall
include imprisonment and/or monetary fines sufficient to provide a
deterrent, consistently with the level of penalties applied for crimes
of a corresponding gravity. In appropriate cases, remedies available
shall also include the seizure, forfeiture and destruction of the
infringing goods and of any materials and implements the
predominant use of which has been in the commission of the
offence. Members may provide for criminal procedures and
penalties to be applied in other cases of infringement of intellectual
property rights, in particular where they are committed wilfully and
on a commercial scale.
2. Analysis
ACTA alters the TRIPS standard by making criminal seizures of
property a remedy for “suspected” violations, instead of proven
infringements.105 This expansion may have the effect of leading to more
criminal seizures of legitimate medicines, particularly when coupled with
the expansion of criminal liability discussed above.
Q. Chapter II, Section 4, Article 25, 2 – SEIZURE, FORFEITURE, AND
DESTRUCTION
Where a Party requires the identification of items subject to
seizure as a prerequisite for issuing an order referred to in
paragraph 1, that Party shall not require the items to be
described in greater detail than necessary to identify them for
105

See ACTA Text–Dec. 3, 2010, supra note 3, art. 25:1 (describing the applicability
of the provision on seizure to “suspect counterfeit trademark goods” and referring to
“alleged” offences).
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the purpose of seizure.

1. Related TRIPS Provisions
[N/A]
2. Analysis
In order to obtain a seizure of goods for merely being “suspected” of a
criminal violation, ACTA imposes a relatively low standard of proof –
ensuring that a country “shall not require the items to be described in
greater detail than necessary to identify them for the purpose of seizure.” 106
This heightened concern for burdens on right holders requesting criminal
seizures of property conflicts with civil and human rights that demand high
evidentiary thresholds for criminal seizures. There is no mention here of
safeguards for the rights and interests of importers – an imbalance that may
lead to more unjustified criminal seizures of medicines in ACTA countries.
CONCLUSION
ACTA proposes to require a broad range of TRIPS-plus measures on
intellectual property enforcement that will predictably lead to increased
burdens on the cross-border trade of medicines to and from developing
countries. The agreement was negotiated behind closed doors within
minimum input from public health and other public interest representatives.
These substance and procedural flaws in the agreement violate specific
commands in multiple EU Parliament resolutions.
Taking into account the analysis above, including of the human rights
obligations and international policy commitments of the EU Parliament, this
opinion advises that the EU Parliament withhold consent to the ACTA
agreement. Parliament should instead reassert the demands of its March 10,
2010, resolution that international intellectual property policy be commited
to “well-established international bodies, such as WIPO and WTO, which
have established frameworks for public information and consultation” and
that any agreements resulting from such process not include TRIPs-plus
measures that raise barriers to cross-border trade in or access to affordable
medications.

106

ACTA Text–Dec. 3, 2010, supra note 3, art. 25:2.
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